Neil Bhattacharyya1, Jeff Grebner, Noel G Martinson. 1. Division of Otolaryngology, Brigham and Women's Hospital, and the Department of Otology and Laryngology, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
OBJECTIVES: To determine the epidemiology of recurrent acute rhinosinusitis (RARS) and to understand direct health care costs attributable to RARS as a potentially underdiagnosed form of chronic rhinosinusitis. STUDY DESIGN: Retrospective longitudinal analysis of a medical claims database. SETTING: Academic medical center. METHODS: Medical claims data (2003-2008) from a large payer database were analyzed. Adult patients with RARS (defined as at least 4 acute rhinosinusitis claims each with a filled oral antibiotic prescription in a 12-month period) were extracted. Sinonasal diagnostic procedures, provider visits, and medical costs were determined. RESULTS: A total of 4588 patients were identified (mean age, 43.5 years; 72.1% female) among 13.1 million patients, for a point prevalence of 0.035%, which remained consistent across years. After 1, 2, and 4 years, 2.4%, 5.4%, and 9.2% of patients subsequently received nasal endoscopy and 11.4%, 23.5%, and 39.9% received paranasal sinus computed tomography, respectively. RARS patients averaged 3.8 antibiotic prescriptions, 5.6 other sinus-related prescriptions, and 5.6 provider visits per year. Total direct health care costs related to RARS averaged $1091/patient-year, with oral antibiotic and nasal prescription costs averaging $210 and $452 per year, respectively. CONCLUSIONS: RARS may affect approximately 1 in 3000 adults per year. Despite significant direct health care costs of more than $1000/year per individual patient with RARS, nasal endoscopy and computed tomography are not commonly obtained early after potential diagnosis. RARS is likely an underdiagnosed condition warranting further study.
OBJECTIVES: To determine the epidemiology of recurrent acute rhinosinusitis (RARS) and to understand direct health care costs attributable to RARS as a potentially underdiagnosed form of chronic rhinosinusitis. STUDY DESIGN: Retrospective longitudinal analysis of a medical claims database. SETTING: Academic medical center. METHODS: Medical claims data (2003-2008) from a large payer database were analyzed. Adult patients with RARS (defined as at least 4 acute rhinosinusitis claims each with a filled oral antibiotic prescription in a 12-month period) were extracted. Sinonasal diagnostic procedures, provider visits, and medical costs were determined. RESULTS: A total of 4588 patients were identified (mean age, 43.5 years; 72.1% female) among 13.1 million patients, for a point prevalence of 0.035%, which remained consistent across years. After 1, 2, and 4 years, 2.4%, 5.4%, and 9.2% of patients subsequently received nasal endoscopy and 11.4%, 23.5%, and 39.9% received paranasal sinus computed tomography, respectively. RARS patients averaged 3.8 antibiotic prescriptions, 5.6 other sinus-related prescriptions, and 5.6 provider visits per year. Total direct health care costs related to RARS averaged $1091/patient-year, with oral antibiotic and nasal prescription costs averaging $210 and $452 per year, respectively. CONCLUSIONS: RARS may affect approximately 1 in 3000 adults per year. Despite significant direct health care costs of more than $1000/year per individual patient with RARS, nasal endoscopy and computed tomography are not commonly obtained early after potential diagnosis. RARS is likely an underdiagnosed condition warranting further study.
Authors: Nithin D Adappa; Carl M Truesdale; Alan D Workman; Laurel Doghramji; Corrine Mansfield; David W Kennedy; James N Palmer; Beverly J Cowart; Noam A Cohen Journal: Int Forum Allergy Rhinol Date: 2016-06-16 Impact factor: 3.858
Authors: Toby O Steele; Jess C Mace; Raj Dedhia; Luke Rudmik; Timothy L Smith; Jeremiah A Alt Journal: Int Forum Allergy Rhinol Date: 2016-06-16 Impact factor: 3.858
Authors: Benjamin M Hariri; Derek B McMahon; Bei Chen; Jenna R Freund; Corrine J Mansfield; Laurel J Doghramji; Nithin D Adappa; James N Palmer; David W Kennedy; Danielle R Reed; Peihua Jiang; Robert J Lee Journal: J Biol Chem Date: 2017-04-03 Impact factor: 5.157
Authors: Benjamin M Hariri; Sakeena J Payne; Bei Chen; Corrine Mansfield; Laurel J Doghramji; Nithin D Adappa; James N Palmer; David W Kennedy; Masha Y Niv; Robert J Lee Journal: Am J Rhinol Allergy Date: 2016-07 Impact factor: 2.467
Authors: Toby O Steele; Kara Y Detwiller; Jess C Mace; E Bradley Strong; Timothy L Smith; Jeremiah A Alt Journal: Laryngoscope Date: 2016-01-09 Impact factor: 3.325
Authors: Daniel M Beswick; Noel F Ayoub; Jess C Mace; Alia Mowery; Peter H Hwang; Timothy L Smith Journal: Laryngoscope Date: 2019-12-14 Impact factor: 3.325